Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market competition.

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be ...

Huge dividends from Denmark’s weight loss drug industry are result of high-tax and high-investment economy, says Nobel Prize winner Morten Meldal.

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

"Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Attorney General Ken Paxton filed a lawsuit this week against Eli Lilly for allegedly bribing Texas health care providers to ...